Ankit Nigam

Ankit Nigam

Followers 1
Following 0
The most thrilling international pharma events, from conferences to meetings & workshops, this is the list not to be missed for pharma professionals.The most important gatherings for producers, suppliers, distributors, buyers and so on..This list will be updated throughout the year!Check out our list of Top 10 Pharmaceutical conferences:  International Conference on Cell and Gene TherapyThe International Research Conference is a federated organization dedicated to bringing together a significant number of diverse scholarly events for presentation within the conference program.Events will run over a span of time during the conference depending on the number and length of the presentations.With its high quality, it provides an exceptional value for students, academics and industry researchers.Location: Paris, FranceDates: July 19-20, 2021View Website: https://waset.org/cell-and-gene-therapy-conference  BIO-Europe Spring 2021BIO-Europe® Spring is held annually in different cities and is an international forum to promote business development between pharmaceutical, financial and biotechnology companies.The event is Europe's largest partnering conference serving the global biotech industry.
(Albany, US) DelveInsight has launched a new report on "Chronic Hepatitis B Virus - Market Insights, Epidemiology, and Market Forecast-2030".DelveInsight's "Chronic Hepatitis B Virus - Market Insights, Epidemiology, and Market Forecast-2030" report delivers an in-depth understanding of the Chronic Hepatitis B Virus , historical and forecasted epidemiology as well as the Chronic Hepatitis B Virus market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.Reports key facts- In 2016, WHO set the target of eliminating chronic HBV as a public health threat by 2030.Elimination of HBV by 2030 will require diagnosis of 90% of people infected with HBV and antiviral treatment of 80% of diagnosed people eligible for therapy.As per DelveInsight’s analysts, the t otal prevalent cases of CHB were 5,797,240 in 2017, which are expected to rise during the study period (2017-2030).Among the 7MM, the United States accounted for nearly 39% of the total prevalent population of CHB in the year 2017.Low diagnosis rate observed across the 7MM and possible factors could be people infected with CHB often have no symptoms and not aware about CHB and also there is overall lack of awareness surrounding HBV necessitates provider education on cut-off values for abnormal levels of alanine aminotransferase (ALT)Request for Sample Page: https://www.delveinsight.com/sample-request/chronic-hepatitis-b-virus-marketView Report: https://www.delveinsight.com/report-store/chronic-hepatitis-b-virus-marketScope of Report:The report covers the descriptive overview of Chronic Hepatitis B Virus , explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapiesComprehensive insight has been provided into the Chronic Hepatitis B Virus epidemiology and treatment in the 7MMAdditionally, an all-inclusive account of both the current and emerging therapies for Chronic Hepatitis B Virus are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscapeA detailed review of Chronic Hepatitis B Virus market; historical and forecasted is included in the report, covering drug outreach in the 7MMThe report provides an edge while developing business strategies, by understanding trends shaping and driving the global Chronic Hepatitis B Virus marketChronic Hepatitis B Virus  is a life-threatening and one of the most common liver infections around the globe.It is caused by the hepatitis B virus (HBV), which attacks and injures the liver.HBV can cause both acute and chronic disease.Having chronic hepatitis B (CHB) increases the risk of developing liver failure, liver cancer or cirrhosis.HBV is mostly transmitted through blood and infected bodily fluids.
(Albany, US) DelveInsight has launched a new report on "Palmar Hyperhidrosis - Market Insights, Epidemiology, and Market Forecast-2030".DelveInsight's "Palmar Hyperhidrosis - Market Insights, Epidemiology, and Market Forecast-2030" report delivers an in-depth understanding of the Palmar Hyperhidrosis, historical and forecasted epidemiology as well as the Palmar Hyperhidrosis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.Some of the Facts:According to the survey, titled “Epidemiological study and considerations of primary focal hyperhidrosis in Japan: From questionnaire analysis” by Fujimoto et al., primary focal hyperhidrosis involving in certain sites, is higher in male than females.As per another survey titled “US prevalence of hyperhidrosis and impact on individuals with axillary hyperhidrosis: Results from a national survey” by Strutton et al., approximately 3% of the US population suffer from hyperhidrosis.According to a study titled “Long-term results of endoscopic thoracic sympathectomy for upper limb hyperhidrosis” by Gossot et al., in a series of 382 French patients treated with endoscopic thoracic sympathectomy (ETS), more than a quarter had palmar and plantar hyperhidrosis, >50% had palmoplantar and axillary hyperhidrosis, less than 10% had palmoplantar and facial hyperhidrosis, 5% had all areas involved, and 8% had axillary hyperhidrosis only.As per the article by Hajjar et al., titled, “The Quality of Life and Satisfaction Rate of Patients With Upper Limb Hyperhidrosis Before and After Bilateral Endoscopic Thoracic Sympathectomy”, hyperhidrosis is a functional disorder identified by excessive sweating and its incidence is approximately 1% in any population.Scope of the ReportThe report covers the descriptive overview of Palmar Hyperhidrosis, explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapiesComprehensive insight has been provided into the Palmar Hyperhidrosis epidemiology and treatment in the 7MMAdditionally, an all-inclusive account of both the current and emerging therapies for Palmar Hyperhidrosis are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscapeA detailed review of Palmar Hyperhidrosis market; historical and forecasted is included in the report, covering drug outreach in the 7MMThe report provides an edge while developing business strategies, by understanding trends shaping and driving the global Palmar Hyperhidrosis marketView Report: https://www.delveinsight.com/report-store/palmar-hyperhidrosis-marketRequest for free sample report: https://www.delveinsight.com/sample-request/palmar-hyperhidrosis-marketPalmar hyperhidrosis, or excessive hand sweating, is a common condition affecting 1-3% of the population.Palmar hyperhidrosis affects both hands equally and can range from mild clammy hands to severe sweating.It stops when sleep.Palmar hyperhidrosis DiagnosisThe diagnosis is usually made based on a history of excessive sweating.No investigations are needed.Palmar hyperhidrosis TreatmentTreatment will depend on how severe the sweating is and which previous treatments have been successful.Topical treatmentsTopical treatments: Some mild to moderate cases can respond to topical treatments such as aluminium chloride hexahydrate (Driclor).Iontophoresis may be considered for cases which do not respond to topical treatments.Botox injections can treat sweaty hands safely and effectively.However, the treatment is not subsidised under Medicare-PBS and the cost limits its wider use.Anticholinergic tablets (such as oxybutynin and propantheline bromide) can be useful in treating palmar hyperhidrosis.
(Albany, US) DelveInsight has launched a new report on "Bradykinesia - Market Insights, Epidemiology, and Market Forecast-2030".DelveInsight's "Bradykinesia - Market Insights, Epidemiology, and Market Forecast-2030" report delivers an in-depth understanding of the Bradykinesia, historical and forecasted epidemiology as well as the Bradykinesia market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.Some of the facts:Up to 98% of all people with Parkinson’s experience slowness of movement.The most common cause of Bradykinesia is Parkinson's disease, and conditions related to Parkinson's disease.More men than women typically develop BradykinesiaView Report: https://www.delveinsight.com/report-store/bradykinesia-marketRequest for free sample report: https://www.delveinsight.com/sample-request/bradykinesia-marketScope of the ReportThe report covers the descriptive overview of Bradykinesia, explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapiesComprehensive insight has been provided into the Bradykinesia epidemiology and treatment in the 7MMAdditionally, an all-inclusive account of both the current and emerging therapies for Bradykinesia are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscapeA detailed review of Bradykinesia market; historical and forecasted is included in the report, covering drug outreach in the 7MMThe report provides an edge while developing business strategies, by understanding trends shaping and driving the global Bradykinesia marketView Report: https://www.delveinsight.com/report-store/bradykinesia-marketRequest for free sample report: https://www.delveinsight.com/sample-request/bradykinesia-marketBradykinesia refers to slowness of movement, and is a common symptom in dopamine-deficient diseases such as AADC deficiency and Parkinson’s disease.Bradykinesia is caused by an imbalance in levels of the neurotransmitter dopamine that is required for proper communication between brain and muscle cells.Bradykinesia is an early sign of AADC deficiency, but is not constantly observed.Periods of normal movement usually alternate with periods of slow movement that affect a patient’s quality of life.Other indications of bradykinesia include micrographia (small or cramped handwriting), hesitation in movement, and noticeably less blinking.Bradykinesia may also develop into hypokinesia (reduced movement) or akinesia (complete loss of movement).Key QuestionsWhat was the Bradykinesia market share (%) distribution in 2017 and how it would look like in 2030?What would be the Bradykinesia total market size as well as market size by therapies across the 7MM during the forecast period (2017-2030)?What are the key findings pertaining to the market across 7MM and which country will have the largest Bradykinesia market size during the forecast period (2017-2030)?At what CAGR, the Bradykinesia market is expected to grow in 7MM during the forecast period (2017-2030)?What would be the Bradykinesia market outlook across the 7MM during the forecast period (2017-2030)?What would be the Bradykinesia market growth till 2030, and what will be the resultant market Size in the year 2030?How would the market drivers, barriers and future opportunities affect the market dynamics and subsequent analysis of the associated trends?What is the disease risk, burden and unmet needs of the Bradykinesia?What is the historical Bradykinesia patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?What would be the forecasted patient pool of Bradykinesia in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?What will be the growth opportunities in the 7MM with respect to the patient population pertaining to Bradykinesia?Out of all 7MM countries, which country would have the highest prevalent population of Bradykinesia during the forecast period (2017-2030)?At what CAGR the population is expected to grow in 7MM during the forecast period (2017-2030)?View Report: https://www.delveinsight.com/report-store/bradykinesia-marketRequest for free sample report: https://www.delveinsight.com/sample-request/bradykinesia-marketTable of Contents:Key InsightsExecutive Summary of BradykinesiaCompetitive Intelligence Analysis for BradykinesiaBradykinesia: Market Overview at a Glance4.1.Bradykinesia Total Market Share (%) Distribution in 20174.2.Bradykinesia Total Market Share (%) Distribution in 2030Bradykinesia: Disease Background and OverviewPatient JourneyBradykinesia Epidemiology and Patient PopulationTreatment Algorithm, Current Treatment, and Medical Practices8.1.
(Albany, US) DelveInsight has launched a new report on "Facioscapulohumeral Muscular Dystrophy - Market Insights, Epidemiology, and Market Forecast-2030".DelveInsight's "Facioscapulohumeral Muscular Dystrophy - Market Insights, Epidemiology, and Market Forecast-2030" report delivers an in-depth understanding of the Facioscapulohumeral Muscular Dystrophy, historical and forecasted epidemiology as well as the Facioscapulohumeral Muscular Dystrophy market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.Some of the facts:As per the “National Organization of Rare Disorders”, FSHD appears to affect males and females in relatively equal numbers.The estimated prevalence is between four and ten per 100,000 people.According to Statland et al.(2016), “Since 1991, studies have shown the worldwide prevalence of FSHD ranging between 2.03 and 6.8 per 100,000 individuals, and the prevalence of FSHD in the United States is commonly quoted as 1 in 15,000 or approximately 21,000 individuals”.According to “FSHD society” 2019, FSHD is the most prevalent of the nine primary types of muscular dystrophy affecting adults and children.It is estimated to affect about 870,000 individuals worldwide, the actual number of individuals with FSHD could be significantly high due to undiagnosed cases.According to “FSHD society” 2019 approximately 95% of FSHD cases are known as Type 1 or FSHD1, which is linked to deletions of D4Z4 units on chromosome 4.The remaining five percent of FSHD cases have normal-length D4Z4 regions on chromosome 4 and are called Type 2 or FSHD2.As per the “Muscular Dystrophy UK” 2019, it is estimated that around 2000–2500 people are affected with FSHD in the United Kingdom.View Report: https://www.delveinsight.com/report-store/facioscapulohumeral-muscular-dystrophy-marketRequest free Sample Report: https://www.delveinsight.com/sample-request/facioscapulohumeral-muscular-dystrophy-marketScope of the Report:The report covers the descriptive overview of Facioscapulohumeral Muscular Dystrophy, explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapiesComprehensive insight has been provided into the Facioscapulohumeral Muscular Dystrophy epidemiology and treatment in the 7MMAdditionally, an all-inclusive account of both the current and emerging therapies for Facioscapulohumeral Muscular Dystrophy are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscapeA detailed review of Facioscapulohumeral Muscular Dystrophy market; historical and forecasted is included in the report, covering drug outreach in the 7MMThe report provides an edge while developing business strategies, by understanding trends shaping and driving the global Facioscapulohumeral Muscular Dystrophy marketRequest free Sample Report: https://www.delveinsight.com/sample-request/facioscapulohumeral-muscular-dystrophy-marketView Report: https://www.delveinsight.com/report-store/facioscapulohumeral-muscular-dystrophy-marketFacioscapulohumeral muscular dystrophy (FSHD) is a disorder characterized by muscle weakness and wasting (atrophy).Severity of the condition varies widely and some people with the disease allele remain asymptomatic.
1
AP-101 acts by promoting the differentiation and migration of keratinocytes (skin cells with wound repair capabilities) as well as transiently increasing the level of proinflammatory mediators (which also promote healing).AP101 has already received marketing approval for the treatment of partial-thickness wounds (PTWs) in adults from the European Commission in January 2016 under the brand name Episalvan.Oleogel-S10 is currently in phase III clinical trial and recently reported positive unblinded interim efficacy and safety analyses.EB-101: Abeona TherapeuticsEB-101 (LZRSE-Col7A1) is an autologous, ex-vivo gene therapy in which the COL7A1 gene is inserted into a patient's skin cells (keratinocytes) for the treatment of the underlying disease in recessive dystrophic epidermolysis bullosa (RDEB).This sheet is then grafted to wounds.The company has evaluated the safety of EB-101 in phase I/II trial in which product has shown significant results, wound treated with EB-101 were significantly healed >50% for more than two years post-administration.CCP-020 (Diacerein 1% Ointment): Castle Creek PharmaceuticalsCCP-020 (Diacerein 1% Ointment) is a topical ointment that is being developed by Castle Creek Pharmaceuticals for the treatment of EBS.reduces the auto-inflammatory effects in the skin of patients with EBS and strengthen epidermal tissue and support healing.Diacerein is a commercially available medicine used to treat osteoarthritis.Earlier a phase II trial of CCP-020 for EBS got terminated because an independent data monitoring committee suggested that the study will not meet statistical objectives.View Report: https://www.delveinsight.com/report-store/epidermolysis-bullosa-marketRequest for free sample report: https://www.delveinsight.com/sample-request/epidermolysis-bullosa-marketCompanies MentionedAmryt PharmaAbeona TherapeuticsCastle Creek PharmaceuticalsRegeneRxKrystal BiotechFibrocell Technologies/Castle Creek PharmaceuticalsRHEACELL GmbHHolostem Terapie AvanzateStemRim/ShionogiPhoenix Tissue Repair (BridgeBio Pharma, Inc)Menlo TherapeuticsJCR PharmaceuticalsAmicus TherapeuticsView Report: https://www.delveinsight.com/report-store/epidermolysis-bullosa-marketRequest for free sample report: https://www.delveinsight.com/sample-request/epidermolysis-bullosa-marketKey Topics Covered: Key Insights Executive Summary of Epidermolysis Bullosa (EB) Epidermolysis Bullosa (EB) Market Overview at a Glance3.1.Managing pain in children with epidermolysis bullosa5.3.
1
(Albany, US) DelveInsight has launched a new report on "Primary Biliary Cirrhosis - Market Insights, Epidemiology, and Market Forecast-2030".DelveInsight's "Primary Biliary Cirrhosis - Market Insights, Epidemiology, and Market Forecast-2030" report delivers an in-depth understanding of the Primary Biliary Cirrhosis, historical and forecasted epidemiology as well as the Primary Biliary Cirrhosis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.Some of the Companies:According to American Association for the Study of Liver Diseases (AASLD), in 2016, the prevalence of PBC in the U.S. was estimated to vary from 1.91 to 40.2 per 100,000 personsIn UK, the prevalence of PBC is estimated to be 12.9 per 100,000 population, of which 90% of cases where reported in womenEpidemiological studies also revealed the prevalence of PBC to be around 27–54 per million cases in JapanAs per one study conducted by Daniel S. Smyk (February 2012), approximately 7–11% of PBC patients are males.View Report: https://www.delveinsight.com/report-store/primary-biliary-cirrhosis-marketRequest for free report: https://www.delveinsight.com/sample-request/primary-biliary-cirrhosis-marketScope of the ReportThe report covers the descriptive overview of Primary Biliary Cirrhosis, explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapiesComprehensive insight has been provided into the Primary Biliary Cirrhosis epidemiology and treatment in the 7MMAdditionally, an all-inclusive account of both the current and emerging therapies for Primary Biliary Cirrhosis are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscapeA detailed review of Primary Biliary Cirrhosis market; historical and forecasted is included in the report, covering drug outreach in the 7MMThe report provides an edge while developing business strategies, by understanding trends shaping and driving the global Primary Biliary Cirrhosis marketPrimary Biliary Cirrhosis (PBC) is a chronic, progressive liver disorder that mostly affects women and usually appears during middle age.It leads to inflammation and scarring of the small bile ducts.If PBC is untreated, it can lead to cirrhosis, or scarring of the entire liver, which can lead to liver failure.PBC is divided into four stages with stage 1 being early disease, where this is no significant scarring, to stage 4, which is defined by cirrhosis.The most common symptom of PBC is fatigue.When PBC is very severe, it can lead to yellow discoloration of the skin (jaundice).PBC is common among women of middle age worldwide.The disease ratio among female to male is 9:1.View Report: https://www.delveinsight.com/report-store/primary-biliary-cirrhosis-marketRequest for free report: https://www.delveinsight.com/sample-request/primary-biliary-cirrhosis-marketSome of the Companies:Axcan PharmaIntercept PharmaceuticalsCalliditas TherapeuticsCymaBay TherapeuticsFast Forward PharmaceuticalsGenkyotexAnd Many OthersDrugs Covered:Ursodeoxycholic acidObeticholic acidNEFECONSeladelparFFP104GKT831And Many OthersView Report: https://www.delveinsight.com/report-store/primary-biliary-cirrhosis-marketRequest for free report: https://www.delveinsight.com/sample-request/primary-biliary-cirrhosis-marketTable of Contents:Key InsightsExecutive Summary of Primary Biliary CirrhosisCompetitive Intelligence Analysis for Primary Biliary CirrhosisPrimary Biliary Cirrhosis: Market Overview at a Glance4.1.Primary Biliary Cirrhosis Total Market Share (%) Distribution in 20174.2.
(Albany, US) DelveInsight has launched a new report on "Pruritus - Market Insights, Epidemiology, and Market Forecast-2030".DelveInsight's "Pruritus - Market Insights, Epidemiology, and Market Forecast-2030" report delivers an in-depth understanding of the Pruritus, historical and forecasted epidemiology as well as the Pruritus market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.Some of the Facts:A 2013 study by Shive et al.reported 77 million visits for itch in America over an 11-year period, with an average of 7 million visits per year, accounting for roughly 1 % of all physician visits.According to the study published by Nicholas et al., the prevalence of pruritus in the general population varies from 8 to 38 % worldwide.The study published by Laurent et al., suggested that in the database maintained by the Münster Competence Centre of Chronic Pruritus, 8% of cases of chronic itch could be associated with a neuropathic origin.As per the study by Emilie et al., the prevalence of patients experiencing pruritus following a burn injury has been noted to be as high as 93%.70–83% of patients continue to be affected by pruritus 1 year after their burn injury, and 67–73% are affected 2 years post-burn injury.Scope of the ReportThe report covers the descriptive overview of Pruritus, explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapiesComprehensive insight has been provided into the Pruritus epidemiology and treatment in the 7MMAdditionally, an all-inclusive account of both the current and emerging therapies for Pruritus are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscapeA detailed review of Pruritus market; historical and forecasted is included in the report, covering drug outreach in the 7MMThe report provides an edge while developing business strategies, by understanding trends shaping and driving the global Pruritus marketView Report: https://www.delveinsight.com/report-store/pruritus-marketRequest for free sample report: https://www.delveinsight.com/report-store/pruritus-marketPruritus, or itching, although considered a benign symptom, is a frequent complaint heard by dermatologists and primary care physicians.It can have adverse effects on a patient’s wellbeing and can be incapacitating when severe.The mechanisms of pruritus are not particularly well understood and are compounded by the subjective nature of the process itself.The condition occurs with a host of dermatological conditions, but can also be a marker of systemic disease.Physiologically, itching is the conscious expression of cutaneous sensations that evoke the well-known scratch reflex.Severe pruritus can be relieved by self-trauma, essentially replacing itching with pain, but such action can result in chronic skin changes, such as lichenification, erythema, excoriation, and even lacerations.Pruritus may be acute or chronic, localized or generalized.
 (Albany, US) DelveInsight has launched a new report on "Primary Progressive Multiple Sclerosis (PPMS) - Market Insights, Epidemiology, and Market Forecast-2030".DelveInsight's "Primary Progressive Multiple Sclerosis (PPMS) - Market Insights, Epidemiology, and Market Forecast-2030" report delivers an in-depth understanding of the Primary Progressive Multiple Sclerosis (PPMS), historical and forecasted epidemiology as well as the Primary Progressive Multiple Sclerosis (PPMS) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.Some of the facts:As per the National Multiple Sclerosis Society, about 15% of the total estimated MS patients in the United States with multiple sclerosis (MS) have the primary progressive form of the disease (PPMS).According to a study by Costa-Arpín et al.(2012), the female to male ratio is generally 1:1 with regard to PPMS and 2 or even 3:1 for relapse onset disease.As seen by changes in the sex ratio, the increasing female preponderance of MS seems to be driven by relapse-onset disease, with the incidence of PPMS remaining relatively constant.View Report: https://www.delveinsight.com/report-store/primary-progressive-multiple-sclerosis-ppms-marketRequest for free sample report: https://www.delveinsight.com/sample-request/primary-progressive-multiple-sclerosis-ppms-marketScope of the ReportThe report covers the descriptive overview of Primary Progressive Multiple Sclerosis (PPMS), explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapiesComprehensive insight has been provided into the Primary Progressive Multiple Sclerosis (PPMS) epidemiology and treatment in the 7MMAdditionally, an all-inclusive account of both the current and emerging therapies for Primary Progressive Multiple Sclerosis (PPMS) are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscapeA detailed review of Primary Progressive Multiple Sclerosis (PPMS) market; historical and forecasted is included in the report, covering drug outreach in the 7MMThe report provides an edge while developing business strategies, by understanding trends shaping and driving the global Primary Progressive Multiple Sclerosis (PPMS) marketView Report: https://www.delveinsight.com/report-store/primary-progressive-multiple-sclerosis-ppms-marketRequest for free sample report: https://www.delveinsight.com/sample-request/primary-progressive-multiple-sclerosis-ppms-marketPrimary-Progressive Multiple Sclerosis (PPMS) is a neurodegenerative disease that interferes with the brain's ability to control the body.There are four main types of MS: relapsing-remitting MS (RRMS), primary-progressive MS (PPMS), secondary-progressive MS (SPMS), and progressive-relapsing MS. Each type might be mild, moderate, or severe.PPMS is characterized by worsening neurologic function (accumulation of disability) from the onset of symptoms, without early relapses or remissions.PPMS can be further characterized at different points in time as either active (with an occasional relapse and/or evidence of new MRI activity) or not active, as well as with progression (evidence of disease worsening on an objective measure of change over time, with or without relapse or new MRI activity) or without progression.The occurrence and severity of PPMS symptoms vary with each person.Symptoms include headaches, pain in the legs and feet, back pain, muscle spasms, trouble in walking, vision problems, etc.
Plaque psoriasis is the most common form of the disease, affecting 80 percent of those with psoriasis.In U.S., the prevalence of Psoriasis is estimated to be 0.6 to 4.8%.125 million people worldwide which is about 2 to 3 percent of the total population have psoriasis, according to the World Psoriasis Day consortium.According to Gulbahar S et al., about 90% of psoriasis cases is plaque psoriasis, which is characterized by "plaques", or raised, red areas of skin covered with a silver or white layer of scale.Psoriasis is considered equally prevalent in both sexes.However, out of all studies that reported prevalence by sex in Global report of Psoriasis by World Health Organization, some of them indicate that psoriasis is more common in men.This issue needs further investigation.View Report: https://www.delveinsight.com/report-store/plaque-psoriasis-marketRequest for free sample report: https://www.delveinsight.com/sample-request/plaque-psoriasis-marketScope of the ReportThe report covers the descriptive overview of Plaque Psoriasis, explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapiesComprehensive insight has been provided into the Plaque Psoriasis epidemiology and treatment in the 7MMAdditionally, an all-inclusive account of both the current and emerging therapies for Plaque Psoriasis are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscapeA detailed review of Plaque Psoriasis market; historical and forecasted is included in the report, covering drug outreach in the 7MMThe report provides an edge while developing business strategies, by understanding trends shaping and driving the global Plaque Psoriasis marketView Report: https://www.delveinsight.com/report-store/plaque-psoriasis-marketRequest for free sample report: https://www.delveinsight.com/sample-request/plaque-psoriasis-marketPsoriasis is a common skin condition that speeds up the life cycle of skin cells.It causes cells to build up rapidly on the surface of the skin.These patches or plaques most often show up on the scalp, knees, elbows and lower back.These bumps generally join together into elevated plaques of skin and most often are visible on the elbows, knees, and scalp, although any area of skin can be involved.
(Albany, US) DelveInsight has launched a new report on "Optic Neuritis - Market Insights, Epidemiology, and Market Forecast-2030".DelveInsight's "Optic Neuritis - Market Insights, Epidemiology, and Market Forecast-2030" report delivers an in-depth understanding of the Optic Neuritis, historical and forecasted epidemiology as well as the Optic Neuritis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.Some of the facts:A rare condition with an estimated annual incidence of 6.4 per 100,000 cases in population in the United States.ON is most common among adults, age 20 to 40 years, and its symptoms generally improve in 80 percent of patients over few weeks.More females are affected than males and approximately five out of every one-hundred thousand people are affected by ON every yearView Report: https://www.delveinsight.com/report-store/optic-neuritis-marketRequest for free sample report: https://www.delveinsight.com/sample-request/optic-neuritis-marketScope of the ReportThe report covers the descriptive overview of Optic Neuritis, explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapiesComprehensive insight has been provided into the Optic Neuritis epidemiology and treatment in the 7MMAdditionally, an all-inclusive account of both the current and emerging therapies for Optic Neuritis are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscapeA detailed review of Optic Neuritis market; historical and forecasted is included in the report, covering drug outreach in the 7MMThe report provides an edge while developing business strategies, by understanding trends shaping and driving the global Optic Neuritis marketOptic Neuritis (ON) is the swelling of the eye’s optic nerve.The optic nerve carries light signals from the back of the eye to the brain so that a person can see.A person cannot see clearly if the optic nerve is swollen, damaged or is infected.It is an acute rare disorder which usually occurs in one eye, and is being characterized by the symptoms including blurring of vision, a loss of part or all of central vision, reduced color vision, and dimness of vision.Most patients with ON have eye pain which characteristically worsen with movement of the eye.View Report: https://www.delveinsight.com/report-store/optic-neuritis-marketRequest for free sample report: https://www.delveinsight.com/sample-request/optic-neuritis-marketSome of the companies covered:BiogenMitochon PharmaceuticalsNoveome BiotherapeuticsAnd Many OthersDrugs Covered:OpicinumabMP101ST266And Many OthersView Report: https://www.delveinsight.com/report-store/optic-neuritis-marketRequest for free sample report: https://www.delveinsight.com/sample-request/optic-neuritis-marketTable of Contents:Key InsightsExecutive Summary of Optic NeuritisCompetitive Intelligence Analysis for Optic NeuritisOptic Neuritis: Market Overview at a Glance4.1.Optic Neuritis Total Market Share (%) Distribution in 2030Optic Neuritis: Disease Background and Overview5.1.Summary of Pivotal Clinical TrialList to be continued in reportEmerging Therapies12.1.Product ProfileList to be continued in reportOptic Neuritis: Seven Major Market Analysis13.1.
Opioid-Induced Constipation Market Analysis, Market Size, Epidemiology, Leading Companies, Drugs and Competitive Analysis by DelveInsight (Albany, US) DelveInsight has launched a new report on "Opioid-Induced Constipation - Market Insights, Epidemiology, and Market Forecast-2030".DelveInsight's "Opioid-Induced Constipation - Market Insights, Epidemiology, and Market Forecast-2030" report delivers an in-depth understanding of the Opioid-Induced Constipation, historical and forecasted epidemiology as well as the Opioid-Induced Constipation market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.Companies covered:AstraZeneca PlcBausch Health Companies Inc.Daiichi Sankyo Co. Ltd.Ironwood Pharmaceuticals Inc.Mallinckrodt PlcMerck & Co. Inc.Novartis AGPfizer Inc.SHIONOGI Co. Ltd.Takeda Pharmaceutical Co. LtdView Report: https://www.delveinsight.com/report-store/opioid-induced-constipation-marketRequest free Sample: https://www.delveinsight.com/report-store/opioid-induced-constipation-marketOpioid-Induced Constipation Epidemiology  The Opioid-Induced Constipation epidemiology division provide insights about historical and current Opioid-Induced Constipation patient pool and forecasted trend for every seven major countries.It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders.Scope of the ReportThe report covers the descriptive overview of Opioid-Induced Constipation, explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapiesComprehensive insight has been provided into the Opioid-Induced Constipation epidemiology and treatment in the 7MMAdditionally, an all-inclusive account of both the current and emerging therapies for Opioid-Induced Constipation are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscapeA detailed review of Opioid-Induced Constipation market; historical and forecasted is included in the report, covering drug outreach in the 7MMThe report provides an edge while developing business strategies, by understanding trends shaping and driving the global Opioid-Induced Constipation market View Report: https://www.delveinsight.com/report-store/opioid-induced-constipation-marketRequest free Sample: https://www.delveinsight.com/report-store/opioid-induced-constipation-market Opioid-induced constipation (OIC) is the most common side effect of opioid therapy because of the distribution of opioid receptors throughout the GI tract.The OIC drug market includes FDA-approved mu opioid receptor antagonists: Shionogi’s Symproic, Salix’s Relistor, and AstraZeneca / Daiichi Sankyo’s Movantik.Opioid-Induced Constipation Market OutlookThe Opioid-Induced Constipation market outlook of the report helps to build the detailed comprehension of the historic, current, and forecasted Opioid-Induced Constipation market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.Opioid-Induced Constipation Total Market Share (%) Distribution in 2030Opioid-Induced Constipation: Disease Background and Overview5.1.
 (Albany, US) DelveInsight has launched a new report on Oral Mucositis Market Insights, Epidemiology and Market Forecast-2030DelveInsight’s “Oral Mucositis (OM) - Market Insights, Epidemiology and Market Forecast - 2030” report provides an overview of the disease and market size of Oral Mucositis for the 7MM major pharmaceutical markets, i.e., the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.This report covers the various treatment practices, and Oral Mucositis forecasted epidemiology from 2020 to 2030, segmented by the 7 major markets.Some of the key facts of the Report:In 2017, US had the maximum number of incident cases of the total incident cases followed by Japan.Grade 3 or 4 Oral Mucositis occurs in around 85% of patients receiving high-dose radiotherapy.In 2017, the incident population of Oral Mucositis in the United States was 1,956,351.)Oral Mucositis market report provides insights on the current and emerging therapies.Oral Mucositis market report offers a global historical and forecasted market covering drug outreach in 7 MM.Oral Mucositis market report provides an edge that will help in developing business strategies by understanding trends shaping and driving the Malignant Mesothelioma market.Request for Sample Pages : https://www.delveinsight.com/sample-request/oral-mucositis-om-market“According to Delveinsight, females appear to be more likely than males to develop Oral mucositis.”View Report: https://www.delveinsight.com/report-store/oral-mucositis-om-marketOral Mucositis (OM) is the most common, debilitating complication of cancer chemotherapy and radiotherapy.It is characterized by inflammation and ulceration in the oral cavity caused by the chemotherapeutic drug substances and radiotherapy used in cancer treatment.The early symptoms include erythema and light discoloration of the mucosa.
 (Albany, US) DelveInsight has launched a new report on "Neuroblastoma Market Insights, Epidemiology, and Market Forecast-2030".DelveInsight's "Neuroblastoma Market Insights, Epidemiology, and Market Forecast-2030" report delivers an in-depth understanding of the Neuroblastoma, historical and forecasted epidemiology as well as the Neuroblastoma market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.Some of the facts:According to DelveInsight, total Incident population of Neuroblastoma in the seven major markets were observed to be more than 1,500 in 2017DelveInsight’s estimate suggest higher incidence of neuroblastoma in the United States, as compared to EU-5 countries and Japan, with 629 Incident population in 2017.Furthermore, the incidence rate of neuroblastoma is increasing at a very slow rate in the United States, has stabilized in the EU5 and in decreasing in Japan for the forecasted period, i.e.2017–2030.As per DelveInsight’s analyst, among the European countries, France has the highest Incident population of Neuroblastoma with 156 cases, followed by the United Kingdom which has Incident population of 147 in 2017.On the other hand, Spain has the lowest Incident population of 90 cases in 2017.Furthermore, according to DelveInsight’s analyst, Japan witnessed more than 250 incident cases of neuroblastoma in 2017.View Report: https://www.delveinsight.com/report-store/neuroblastoma-marketRequest Sample: https://www.delveinsight.com/sample-request/neuroblastoma-marketScope of the ReportThe Neuroblastoma report covers the descriptive overview of Neuroblastoma, explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapiesComprehensive insight has been provided into the Neuroblastoma epidemiology and treatment in the 7MMAdditionally, an all-inclusive account of both the current and emerging therapies for Neuroblastoma are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscapeA detailed review of Neuroblastoma market; historical and forecasted is included in the report, covering drug outreach in the 7MMThe Neuroblastoma report provides an edge while developing business strategies, by understanding trends shaping and driving the global Neuroblastoma marketView Report: https://www.delveinsight.com/report-store/neuroblastoma-marketRequest Sample: https://www.delveinsight.com/sample-request/neuroblastoma-marketNeuroblastoma is an embryonal malignancy of the sympathetic nervous system arising from neuroblasts (pluripotent sympathetic cells).It is derived from two words i.e.“neuro” means nerves and “blastoma” refers to the tumor affecting the immature or developing cells.
 (Albany, US) DelveInsight's "Myelofibrosis - Market Insights, Epidemiology, and Market Forecast-2030".DelveInsight's "Myelofibrosis - Market Insights, Epidemiology, and Market Forecast-2030" report delivers an in-depth understanding of the Myelofibrosis, historical and forecasted epidemiology as well as the Myelofibrosis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.Some of the facts:The incidence was estimated to be 0.5 cases per 100,000 people.Approximately, 50 percent of people with PMF have a mutation of the JAK2 gene.In younger children, girls are affected twice as often as boys.Primary Myelofibrosis is a rare condition that affects approximately 1 in 500,000 people worldwide.Myelofibrosis affects males and females in equal numbers.View Report: https://www.delveinsight.com/report-store/myelofibrosis-marketRequest for free sample: https://www.delveinsight.com/sample-request/myelofibrosis-marketScope of the ReportThe report covers the descriptive overview of Myelofibrosis, explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapiesComprehensive insight has been provided into the Myelofibrosis epidemiology and treatment in the 7MMAdditionally, an all-inclusive account of both the current and emerging therapies for Myelofibrosis are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscapeA detailed review of Myelofibrosis market; historical and forecasted is included in the report, covering drug outreach in the 7MMThe report provides an edge while developing business strategies, by understanding trends shaping and driving the global Myelofibrosis marketView Report: https://www.delveinsight.com/report-store/myelofibrosis-marketRequest for free sample: https://www.delveinsight.com/sample-request/myelofibrosis-marketMyelofibrosis (MF) is a disorder in which normal bone marrow tissue is gradually replaced with a fibrous scar-like material.It is classified as a type of chronic leukemia and belongs to a group of blood disorders called myeloproliferative diseases.Over time, this leads to progressive bone marrow failure.Specialised cells in the bone marrow known as fibroblasts make these fibres.Myelofibrosis can be of two types:Primary myelofibrosis (also called Chronic Idiopathic Myelofibrosis, agnogenic myeloid metaplasia) develops on its own, due to certain genetic mutations.It occurs most often between age 50 and 70 years, mostly in men.Secondary myelofibrosis occurs as a result of other disorders, particularly other blood disorders such as chronic myeloid leukemia, polycythemia vera, thrombocythemia, multiple myeloma, and lymphoma.Initially, most people with primary myelofibrosis have no signs or symptoms.A shortage of red blood cells (anemia) often causes extreme tiredness (fatigue) or shortness of breath.
 (Albany, US) DelveInsight launched its new report on Osteosarcoma Market Insights, Epidemiology and Market Forecast 2030.DelveInsight’s “Osteosarcoma Market Insights, Epidemiology, and Market Forecast-2030″ report delivers an in-depth understanding of the Osteosarcoma, historical and forecasted epidemiology as well as the Osteosarcoma market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.Some of the key facts of the report:Osteosarcoma (OS) is a relatively rare tumour of bone with a worldwide Prevalence of 3.4 cases per million people per yearApproximately 800 to 900 new cases of Osteosarcoma are diagnosed in the U.S. every year.About 2% of childhood cancers are osteosarcomas, but they make up a much smaller percentage of adult cancers.View Report: https://www.delveinsight.com/report-store/osteosarcoma-marketRequest Sample: https://www.delveinsight.com/sample-request/osteosarcoma-marketKey benefits of the report:Osteosarcoma market report covers a descriptive overview and comprehensive insight of the Osteosarcoma epidemiology and Osteosarcoma market in the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.Osteosarcoma market report provides insights on the current and emerging therapies.Osteosarcoma market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Osteosarcoma market.View Report: https://www.delveinsight.com/report-store/osteosarcoma-marketRequest Sample: https://www.delveinsight.com/sample-request/osteosarcoma-market “The World Health Organization’s histologic classification of bone tumors divides OS into Central, Intramedullary and Surface tumors.”Stages of osteosarcoma:Localized-The tumour is only in the bone where it began and in the tissue around it.Most often, it spreads to the lungs or other bones.Recurrent-Recurrent osteosarcoma is a tumour that has come back during or after treatment.This is called re-staging.The key pharma players in Osteosarcoma market are:Eleison PharmaceuticalsAadi BioscienceCellectar BiosciencesAnd Many OthersView Report: https://www.delveinsight.com/report-store/osteosarcoma-marketRequest Sample: https://www.delveinsight.com/sample-request/osteosarcoma-marketEmerging Drugs:Inhaled lipid-complexed cisplatinABI-009CLR 131And Many OthersTable of contents:Report Introduction 2.
 DelveInsight has launched a report on “Polycythemia Vera - Market Insights, Epidemiology, and Market Forecast-2030”DelveInsight's "Polycythemia Vera - Market Insights, Epidemiology, and Market Forecast-2030" report delivers an in-depth understanding of the Polycythemia Vera , historical and forecasted epidemiology as well as the Polycythemia Vera market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.Polycythemia Vera market report offers a global historical and forecasted market covering drug outreach in 7MM.Polycythemia Vera market report provides an edge that will help in developing business strategies by understanding trends shaping and driving the Polycythemia Vera market.These new cells cause the blood to be thicker than usual, increasing the risk for blood clots that can block blood flow in arteries and veins.Most cases of PV are associated with genetic changes that are somatic, not in the egg and sperm cells, which pass on genetic information to offspring.The diagnosis of PV is done by testing the blood for levels of a hormone called erythropoietin or testing the blood for mutations in JAK2.The diagnostic test also includes Complete blood count (CBC) to measure the number and quality of WBCs, RBCs, and platelets.View Report: https://www.delveinsight.com/report-store/polycythemia-vera-marketSome of the key companies working on Polycythemia Vera are:AstraZenecaArray BiopharmaSpringWorks TherapeuticsAnd Many Others.The launch of the emerging therapies is expected to significantly impact the Polycythemia Vera treatment scenario in the upcoming years:- Drugs Covered:Jakafi (Ruxolitinib): Incyte Corporation/NovartisBesremi: AOP Orphan Pharmaceuticals AG/ PharmaEssentiaIdasanutlin: Hoffmann-La RocheKRT-232: Kartos TherapeuticsAnd Many Others002ERequest for Sample Pages: https://www.delveinsight.com/sample-request/polycythemia-vera-marketView Report: https://www.delveinsight.com/report-store/polycythemia-vera-marketTable of Contents:Key InsightsExecutive SummaryPolycythemia Vera (PV) Market Overview at a Glance3.1.Market Size of Polycythemia Vera by therapies in the UKJapan Market Outlook17.1.
 (Albany, US) DelveInsight has launched a new report on "Acute On Chronic Liver Failure (ACLF) - Market Insights, Epidemiology, and Market Forecast-2030".DelveInsight's "Acute On Chronic Liver Failure (ACLF) - Market Insights, Epidemiology, and Market Forecast-2030" report delivers an in-depth understanding of the Acute On Chronic Liver Failure (ACLF) , historical and forecasted epidemiology as well as the Acute On Chronic Liver Failure (ACLF) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.Some of the facts:Although a uniformly accepted definition for epidemiological studies is lacking, ACLF is the most life-threatening complication of cirrhosis.According to the US-national cohort study by Hernaez et al., of 72,316 patients hospitalized for decompensated cirrhosis, 26.4% (19,082) patients met the criteria of ACLF on admission.Of these, 12.8% had one, 10.1% had two, and 3.5% had three or more organ failures, respectively.Europe-based study analyzed the data from 1343 patients with cirrhosis and acute liver decompensation.The study reported a prevalence of ACLF as 30.9% and was associated with a short-term (28-day) mortality, i.e., 15 times higher than in cirrhotic patients without ACLF.)According to the study in Italy by Piano et al., it has been observed that among the 466 patients with cirrhosis, 118 patients (25%) were reported to develop ACLF, in which the number of patients 57; 33; and 28 belonged to grade-1, grade-2, and grade-3 ACLF, respectively.The study concluded that outpatients with cirrhosis have a high risk of developing ACLF.View Report: https://www.delveinsight.com/report-store/acute-on-chronic-liver-failure-aclf-marketRequest Sample: https://www.delveinsight.com/sample-request/acute-on-chronic-liver-failure-aclf-marketScope of the ReportThe report covers the descriptive overview of Acute On Chronic Liver Failure (ACLF) , explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapiesComprehensive insight has been provided into the Acute On Chronic Liver Failure (ACLF) epidemiology and treatment in the 7MMAdditionally, an all-inclusive account of both the current and emerging therapies for Acute On Chronic Liver Failure (ACLF) are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscapeA detailed review of Acute On Chronic Liver Failure (ACLF) market; historical and forecasted is included in the report, covering drug outreach in the 7MMThe report provides an edge while developing business strategies, by understanding trends shaping and driving the global Acute On Chronic Liver Failure (ACLF) marketView Report: https://www.delveinsight.com/report-store/acute-on-chronic-liver-failure-aclf-marketRequest Sample: https://www.delveinsight.com/sample-request/acute-on-chronic-liver-failure-aclf-marketThe term ACLF was first introduced in 1995 to describe a condition in which two “lesions” or “insults” act simultaneously on the liver, one of which is chronic and the other is acute.
 (Albany, US) DelveInsight has launched a new report on Epilepsy MarketDelveInsight’s “Epilepsy- Market Insights, Epidemiology, and Market Forecast-2030” report delivers an in-depth understanding of the Epilepsy, historical and forecasted epidemiology as well as the Epilepsy market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.The Epilepsy market report provides current treatment practices, emerging drugs, Epilepsy market share of the individual therapies, current and forecasted Epilepsy market Size from 2017 to 2030 segmented by seven major markets.The Report also covers current Epilepsy treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.View free sample page:-  https://www.delveinsight.com/sample-request/epilepsy-marketView Report: https://www.delveinsight.com/report-store/epilepsy-marketEpilepsy MarketDelveInsight’s assessment based on the recent studies and data from registries shows that the EU5 countries and US  accounts for the 30.34% and 51.41%, respectively, of the total prevalent cases out of all the Epilepsy cases in 7 major markets in 2017.DelveInsight estimated the highest percentage of diagnosed prevalent populationof Epilepsy in the UK followed by Germany among the EU5 countries based on the recent studies and data from the registries of 2017.View Report: https://www.delveinsight.com/report-store/epilepsy-marketEpilepsy Market OutlookThe Epilepsy market outlook of the report helps to build the detailed comprehension of the historic, current, and forecasted Epilepsy market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.
View report: https://www.delveinsight.com/report-store/cervical-cancer-marketSome of the key insights from cervical cancer market report: The incidence of cervical cancer in 7MM (US, UK, Germany, Italy, Spain, France & Japan) in 2020 is expected to be 43,712.In the 7MM, the USA is the major contributor to the cervical cancer market revenue in 2020, and the region is expected to hold its position in the upcoming years.Key companies propelling the market size include Regeneron, AstraZeneca, Lovance, Zeria Pharmaceutical, Seattle Genetics/Genmab, Agenus Bio, Roche, Akeso Biopharma and Vaccibody/Roche, among others.Launch of cervical cancer pipeline therapies, including Cemiplimab (Regeneron), Durvalumab (AstraZeneca), LN-145 (Iovance), Z-100 (Zeria Pharmaceutical), Tisotumab vedotin (Seattle Genetics/Genmab) in the next decade is expected to propel the market growth.Get a cervical cancer sample copy or download a cervical cancer infograph: www.delveinsight.com/sample-request/cervical-cancer-marketView report: https://www.delveinsight.com/report-store/cervical-cancer-marketCervical cancer is a cause of infection from Human papillomavirus (HPV), which can be prevented.However, a lack of awareness and misconceptions hinder screening and its early diagnosis.To know more about Cervical Cancer Incidence, Diagnosis and Mortality Visit: https://www.delveinsight.com/report-store/cervical-cancer-market View report: https://www.delveinsight.com/report-store/cervical-cancer-marketThe cervical cancer epidemiology section in the report provides historical and forecasted analysis upto 2030 segmented by:Incident cases of Cervical CancerStage-specific Incidence of Cervical CancerHistopathologic Types of Cervical Cancer Age-specific causes of Cervical CancerThe present treatment market for cervical cancer is mainly bifurcated into therapeutics and preventive.Recently, at ASCO 2020, Genmab demonstrated the positive benefit-to-risk profile of its drug Tisotumab vedotin, a first-in-class antibody-drug conjugate directed against tissue factor (TF).Now the company plans to investigate the drug in combination with other cancer drugs, namely Bevacizumab, Pembrolizumab, and Carboplatin in a Phase Ib/II trial to find out the correct dosage in recurrent or metastatic cervical cancer (NCT03786081).Nevertheless, the renewed interest in targeted therapies, personalized medicine, and rising R that has facilitated the identification of actionable biomarkers offer a promising and flourishing environment to the global cervical cancer market.
More

Top